EE200100293A - Controlled release dosage form containing GnRH-II - Google Patents

Controlled release dosage form containing GnRH-II

Info

Publication number: EE200100293A
Authority: EE; Estonia
Prior art keywords: dosage form; controlled release; release dosage; form containing; containing gnrh
Prior art date: 1998-12-03

Application number

EEP200100293A

Other languages

Estonian (et)

Inventor

Qi Steve

Akinsanya Karen

Hayward Amanda

Original Assignee

Ferring B.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-03

Filing date

1999-12-02

Publication date

2002-08-15

1999-12-02 Application filed by Ferring B.V. filed Critical Ferring B.V.

2002-08-15 Publication of EE200100293A publication Critical patent/EE200100293A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

EEP200100293A 1998-12-03 1999-12-02 Controlled release dosage form containing GnRH-II EE200100293A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB9826662A GB2344287A (en)	1998-12-03	1998-12-03	Controlled release pharmaceutical formulation
PCT/GB1999/004045 WO2000032218A1 (en)	1998-12-03	1999-12-02	Controlled release formulation comprising gnrh-ii

Publications (1)

Publication Number	Publication Date
EE200100293A true EE200100293A (en)	2002-08-15

Family

ID=10843631

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200100293A EE200100293A (en)	1998-12-03	1999-12-02	Controlled release dosage form containing GnRH-II

Country Status (22)

Country	Link
EP (1)	EP1140133A1 (en)
JP (1)	JP2002531411A (en)
KR (1)	KR20010089538A (en)
CN (1)	CN1332635A (en)
AU (1)	AU770676B2 (en)
BR (1)	BR9915943A (en)
CA (1)	CA2353798A1 (en)
CZ (1)	CZ20011893A3 (en)
EE (1)	EE200100293A (en)
GB (1)	GB2344287A (en)
HR (1)	HRP20010421A2 (en)
HU (1)	HUP0104943A3 (en)
IL (1)	IL143496A0 (en)
MX (1)	MXPA01005543A (en)
NO (1)	NO20012636L (en)
NZ (1)	NZ511984A (en)
PL (1)	PL348575A1 (en)
RU (1)	RU2233170C2 (en)
SK (1)	SK7552001A3 (en)
TR (1)	TR200102273T2 (en)
WO (1)	WO2000032218A1 (en)
ZA (1)	ZA200104530B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8334258B2 (en)	2005-07-26	2012-12-18	Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts (Universitätsmedizin)	Method for induction and enhancement of apoptosis in tumor cells
GB0616111D0 (en)	2006-06-16	2006-09-20	Ardana Bioscience Ltd	Agents, methods and uses
US8563513B2 (en)	2009-03-27	2013-10-22	Van Andel Research Institute	Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
WO2011032099A1 (en)	2009-09-11	2011-03-17	The Board Of Trustees Of The University Of Illinois	Methods of treating diastolic dysfunction and related conditions
US20120208762A1 (en)	2009-10-27	2012-08-16	The Board Of Trustees Of The University Of Illinois	Methods of Diagnosing Diastolic Dysfunction
WO2011075393A2 (en)	2009-12-18	2011-06-23	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
US8551946B2 (en)	2010-01-27	2013-10-08	Indiana University Research And Technology Corporation	Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
WO2011116026A2 (en)	2010-03-15	2011-09-22	The Board Of Trustees Of The University Of Illinois	Inhibitors of beta integrin-g protein alpha subunit binding interactions
WO2011159895A2 (en)	2010-06-16	2011-12-22	Indiana University Research And Technology Corporation	Single chain insulin agonists exhibiting high activity at the insulin receptor
US20120004182A1 (en)	2010-07-02	2012-01-05	Carsten Gruendker	Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
US9029502B2 (en)	2010-12-20	2015-05-12	The Regents Of The University Of Michigan	Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
EP2654773B1 (en)	2010-12-22	2018-10-03	Indiana University Research and Technology Corporation	Glucagon analogs exhibiting gip receptor activity
JP6179864B2 (en)	2011-06-22	2017-08-16	インディアナユニヴァーシティリサーチアンドテクノロジーコーポレイション	Glucagon / GLP-1 receptor co-agonist
US9415123B2 (en)	2011-10-10	2016-08-16	The Regents Of The University Of Michigan	Polymeric nanoparticles for ultrasound imaging and therapy
JP6324315B2 (en)	2011-11-17	2018-05-16	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	Glucagon superfamily of peptides exhibiting glucocorticoid receptor activity
CN104114183A (en)	2011-12-20	2014-10-22	印第安纳大学研究及科技有限公司	CTP-based insulin analogs for treatment of diabetes
US20150152187A1 (en)	2012-06-14	2015-06-04	Ambrx, Inc.	Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides
EP2864351B1 (en)	2012-06-21	2016-08-10	Indiana University Research and Technology Corporation	Glucagon analogs exhibiting gip receptor activity
PT2864350T (en)	2012-06-21	2018-05-14	Hoffmann La Roche	Analogs of glucagon exhibiting gip receptor activity
US9593156B2 (en)	2012-09-26	2017-03-14	Indiana University Research And Technology Corporation	Insulin analog dimers
RU2678134C2 (en)	2013-03-14	2019-01-23	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Insulin-incretin conjugates
US10189908B2 (en)	2014-02-05	2019-01-29	The University Of Chicago	Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
US10232020B2 (en)	2014-09-24	2019-03-19	Indiana University Research And Technology Corporation	Incretin-insulin conjugates
US20180170992A1 (en)	2015-01-26	2018-06-21	The University Of Chicago	CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
US10308719B2 (en)	2015-01-26	2019-06-04	The University Of Chicago	IL13Rα2 binding agents and use thereof in cancer treatment
CN104789524A (en) *	2015-04-30	2015-07-22	四川大学	Osteoporotic rat primary osteoblasts isolated culture method and application thereof
US20180201937A1 (en)	2015-08-04	2018-07-19	The University Of Chicago	Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
JP2020505379A (en) *	2017-01-20	2020-02-20	イミューンシステムレギュレェイションホールディングエービー	Novel compound (immunorelin)
PL3645002T3 (en)	2017-06-30	2025-03-24	Amgen Inc.	METHODS OF TREATMENT OF HEART FAILURE USING CARDIAC SARCOMERE ACTIVATORS
US11541103B2 (en)	2017-08-03	2023-01-03	Amgen Inc.	Interleukin-21 mutein/ anti-PD-1 antibody conjugates
UY37870A (en)	2017-09-08	2019-03-29	Amgen Inc	KRAS G12C INHIBITORS AND METHODS TO USE THEM FIELD OF THE INVENTION
HUE067603T2 (en)	2017-09-18	2024-10-28	Univ California	Claudin6 antibodies and methods of treating cancer
MX2020007291A (en)	2018-01-12	2020-09-10	Amgen Inc	Anti-pd-1 antibodies and methods of treatment.
WO2020055913A1 (en)	2018-09-10	2020-03-19	Cardax, Inc.	Methods of reducing- c-reactive protein and/or treating cardiovascular disease
CA3134056A1 (en)	2019-03-20	2020-09-24	The Regents Of The University Of California	Claudin-6 bispecific antibodies
CA3134055A1 (en)	2019-03-20	2020-09-24	The Regents Of The University Of California	Claudin-6 antibodies and drug conjugates
AU2019437315B2 (en)	2019-03-26	2022-10-06	Novel Pharma Inc.	Long-acting fatty acid-binding GnRH derivative and pharmaceutical composition comprising same
US20220160872A1 (en)	2019-04-09	2022-05-26	The Board Of Trustees Of The University Of Illinois	Drug Adsorbed Highly Porous Activated Carbon for Enhanced Drug Delivery
US20230190725A1 (en)	2019-04-29	2023-06-22	The Board Of Trustees Of The University Of Illinois	Mek inhibitors for corneal scarring and neovascularization
KR20220002316A (en)	2019-04-30	2022-01-06	인스티튜토 데 메디시나 몰레큘라 조앙 로보 안투네스	RANK pathway inhibitors in combination with CDK inhibitors
WO2020263793A1 (en)	2019-06-24	2020-12-30	Amgen Inc.	Inhibition of sirp-gamma for cancer treatment
JP2022546700A (en)	2019-08-30	2022-11-07	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	Copper-ATSM for the treatment of neurodegenerative disorders associated with mitochondrial dysfunction
TW202216778A (en)	2020-07-15	2022-05-01	美商安進公司	Tigit and cd112r blockade
KR20230107282A (en)	2020-11-12	2023-07-14	암젠 인크	Methods of administering omecamtib mecabil to treat heart failure
WO2022159575A1 (en)	2021-01-20	2022-07-28	Bioentre Llc	Ctla4-binding proteins and methods of treating cancer
WO2023137161A1 (en)	2022-01-14	2023-07-20	Amgen Inc.	Triple blockade of tigit, cd112r, and pd-l1
US11986474B1 (en)	2023-06-27	2024-05-21	Cytokinetics, Incorporated	Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH661206A5 (en) *	1983-09-23	1987-07-15	Debiopharm Sa	PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HORMONDEPENDENT DISEASES.
DE3414595A1 (en) *	1984-04-18	1985-10-31	Hoechst Ag, 6230 Frankfurt	USE OF GONADOLIBERIN AND GONADOLIBERINAGONISTS FOR TREATING CLIMATE COMPLAINTS
US4540513A (en) *	1984-09-25	1985-09-10	Kanegafuchi Kagaku Kogyo Kabushiki Kaisha	Decapeptide having gonadotropin releasing activity
US4721775A (en) *	1985-08-26	1988-01-26	Board Of Regents, The University Of Texas System	Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
DE3634435A1 (en) *	1986-10-09	1988-04-14	Hoechst Ag	ANALOGA OF GONADOLIBERIN WITH IMPROVED SOLUBILITY, METHOD FOR THE PRODUCTION THEREOF, THE CONTAINERS THEREOF AND THEIR USE
NO302481B1 (en) *	1990-10-16	1998-03-09	Takeda Chemical Industries Ltd	Polymer for an extended release preparation, as well as an extended release preparation
IT1243390B (en) *	1990-11-22	1994-06-10	Vectorpharma Int	PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
CA2192773C (en) *	1995-12-15	2008-09-23	Hiroaki Okada	Production of sustained-release preparation for injection
AU3388597A (en) *	1996-06-13	1998-01-07	University Of Cape Town	Human type ii gonadotropin-releasing hormone receptor
US5932547A (en) *	1996-07-03	1999-08-03	Alza Corporation	Non-aqueous polar aprotic peptide formulations
GB2343182A (en) *	1998-10-27	2000-05-03	Ferring Bv	Use of GnRH-II and analogues thereof for the treatment of osteoporosis

1998
- 1998-12-03 GB GB9826662A patent/GB2344287A/en not_active Withdrawn
1999
- 1999-12-02 CZ CZ20011893A patent/CZ20011893A3/en unknown
- 1999-12-02 EE EEP200100293A patent/EE200100293A/en unknown
- 1999-12-02 CN CN99815183A patent/CN1332635A/en active Pending
- 1999-12-02 KR KR1020017006883A patent/KR20010089538A/en not_active Withdrawn
- 1999-12-02 MX MXPA01005543A patent/MXPA01005543A/en unknown
- 1999-12-02 BR BR9915943-0A patent/BR9915943A/en not_active IP Right Cessation
- 1999-12-02 RU RU2001118040/15A patent/RU2233170C2/en not_active IP Right Cessation
- 1999-12-02 PL PL99348575A patent/PL348575A1/en not_active Application Discontinuation
- 1999-12-02 NZ NZ511984A patent/NZ511984A/en unknown
- 1999-12-02 CA CA002353798A patent/CA2353798A1/en not_active Abandoned
- 1999-12-02 SK SK755-2001A patent/SK7552001A3/en unknown
- 1999-12-02 WO PCT/GB1999/004045 patent/WO2000032218A1/en not_active Ceased
- 1999-12-02 IL IL14349699A patent/IL143496A0/en unknown
- 1999-12-02 HU HU0104943A patent/HUP0104943A3/en unknown
- 1999-12-02 JP JP2000584909A patent/JP2002531411A/en active Pending
- 1999-12-02 HR HR20010421A patent/HRP20010421A2/en not_active Application Discontinuation
- 1999-12-02 TR TR2001/02273T patent/TR200102273T2/en unknown
- 1999-12-02 AU AU15732/00A patent/AU770676B2/en not_active Ceased
- 1999-12-02 EP EP99958357A patent/EP1140133A1/en not_active Withdrawn
2001
- 2001-05-29 NO NO20012636A patent/NO20012636L/en not_active Application Discontinuation
- 2001-06-01 ZA ZA200104530A patent/ZA200104530B/en unknown

Also Published As

Publication number	Publication date
IL143496A0 (en)	2002-04-21
EP1140133A1 (en)	2001-10-10
TR200102273T2 (en)	2001-12-21
HUP0104943A3 (en)	2002-08-28
HRP20010421A2 (en)	2002-06-30
NO20012636L (en)	2001-07-12
NZ511984A (en)	2002-11-26
AU770676B2 (en)	2004-02-26
NO20012636D0 (en)	2001-05-29
MXPA01005543A (en)	2003-07-14
ZA200104530B (en)	2002-06-04
CZ20011893A3 (en)	2002-05-15
GB9826662D0 (en)	1999-01-27
CN1332635A (en)	2002-01-23
WO2000032218A1 (en)	2000-06-08
KR20010089538A (en)	2001-10-06
CA2353798A1 (en)	2000-06-08
AU1573200A (en)	2000-06-19
HUP0104943A2 (en)	2002-06-29
BR9915943A (en)	2001-08-21
SK7552001A3 (en)	2002-02-05
PL348575A1 (en)	2002-06-03
JP2002531411A (en)	2002-09-24
GB2344287A (en)	2000-06-07
RU2233170C2 (en)	2004-07-27

Publication	Publication Date	Title
EE200100293A (en)	2002-08-15	Controlled release dosage form containing GnRH-II
TR200003788A3 (en)	2001-07-23	Yavas release oral dosage composition.
ATE392890T1 (en)	2008-05-15	HYDROGEL-CONTROLLED DOSAGE FORM
ZA99454B (en)	2000-10-23	Novel dosage form.
DE69834019D1 (en)	2006-05-18	can
DK1600154T3 (en)	2011-02-21	Extended release osmotic dosage form
ATE298748T1 (en)	2005-07-15	(1,4')-BIPIPERIDINE COMPOUNDS
MX238612B (en)	2006-07-12	COMPOUNDS CONTAINING SUPERABSORBENT.
TR199901077A3 (en)	1999-12-21	Pharmaceutical formulations.
DE69928777D1 (en)	2006-01-12	DOSAGE DISPENSER
ZA200108000B (en)	2002-11-27	Cosmetic compounds.
NO20005913L (en)	2001-01-22	Medicinal Composition
ZA200007715B (en)	2001-06-20	Stable extended release oral dosage composition.
ZA993345B (en)	2000-08-22	Nefazodone dosage form.
DE59900501D1 (en)	2002-01-17	SOLID, QUICK-DISINTERABLE CETIRIZINE FORMULATIONS
BR0014932B1 (en)	2009-01-13	retention set.
IT1321100B1 (en)	2003-12-30	BRAKE INTERLOCKING DEVICE.
IT1309578B1 (en)	2002-01-24	PIGMENTED PHOTOINDURABLE COMPOSITION.
ID22228A (en)	1999-09-23	16-HYDROXY-11- (DISUBSTITUSIFENIL) -ESTRA-4,9-DIENA
MXPA03001425A (en)	2003-06-06	PHARMACEUTICAL COMPOUNDS.
DE50015811D1 (en)	2010-01-14	retarder
EE200000022A (en)	2000-10-16	New dosage form
MXPA01011760A (en)	2003-09-04	NEW DIFENILETILENE COMPOUNDS.
DE60025958D1 (en)	2006-04-20	14,15-BETA-METHYLENE SUBSTITUTED ANDROGENE
TR199901017A3 (en)	1999-12-21	Insecticide composition.